We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PRECOS to Unveil New Service Portfolio at Cancer Targets & Therapeutics and AACR 2012
News

PRECOS to Unveil New Service Portfolio at Cancer Targets & Therapeutics and AACR 2012

PRECOS to Unveil New Service Portfolio at Cancer Targets & Therapeutics and AACR 2012
News

PRECOS to Unveil New Service Portfolio at Cancer Targets & Therapeutics and AACR 2012

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PRECOS to Unveil New Service Portfolio at Cancer Targets & Therapeutics and AACR 2012"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Preclinical Oncology Services Limited (PRECOS) will be showcasing several new platforms for pre-clinical oncology research at two leading shows: Cancer Targets & Therapeutics, Las Vegas, February 27th - 28th and AACR, Chicago, March 31st - April 4th 2012.

PRECOS leads the way in providing robust models, validated against today’s Standard Of Care agents to enable pre-clinical in vitro and in vivo testing of the next generation of oncology candidate drugs.

The International Agency for Research on Cancer (IARC) forecasts that by 2030 there will be over 26 million new cases and 17 million deaths per year from cancer.

PRECOS will be launching several new cutting-edge services at the North American shows which support target validation and drug screening early in the research process for anti-cancer activity.

The company provides expertise, specialism and innovation to small to medium biotechnology companies and the new platforms will support new and existing projects going forward.

At the shows PRECOS will highlight how it can deliver a customized screening platform either in 2-D or 3-D in vitro and/or in vivo that can far more closely model the development of cancer and therefore more accurately reflect the effect of potential candidate entities.

Cell lines created from patient primary tissue that “never see plastic” are selected based their true characteristics as cancer cells, instead of their ability to survive in vitro.

Dr Neil Rotherham, chairman of PRECOS comments, “The new service lines demonstrate our commitment to offer a world-class service and the platforms provide significant benefits to clients. We are excited to talk to existing and potential clients from around the world at these leading events to demonstrate the breadth of solutions we can offer them for their oncology research and development needs."

The 2012 3rd Cancer Targets & Therapeutics Conference examines new and emerging targets and therapeutics in the area of cancer research.

Speakers at the event provide case studies of emerging targets in order to address some of the issues surrounding target-based drug discovery and development.

The AACR Annual Meeting will highlight the best and latest findings in all major areas of cancer research.

PRECOS’ full service offering will be highlighted at Cancer Targets & Therapeutics 2012 and on booth #4306 at AACR 2012.

Advertisement